Pathogenesis of rheumatoid arthritis: Targeting cytokines

Annals of the New York Academy of Sciences

Volumn 1051, Issue , 2005, Pages 716-729

  Zwerina, Jochen ^a   Redlich, Kurt ^a   Schett, Georg ^a   Smolen, Josef S ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Division of Rheumatology   (Austria)

Author keywords

Anti IL 6R (MRA); Anti TNF; Cytokines; Disease activity; IL 1; IL 15; IL 1ra; IL 6; Joint damage; Osteoclasts; Rheumatoid arthritis; Therapy; TNF

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 PLUS IMMUNOGLOBULIN G FC DOMAIN; INTERLEUKIN 15; INTERLEUKIN 15 ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; PEGSUNERCEPT; PRALNACASAN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CONFERENCE PAPER; DISEASE ACTIVITY; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; NONHUMAN; OSTEOCLAST; PATHOGENESIS; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS;

EID: 25444508411     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1361.116     Document Type: Conference Paper

References (106)

1. WEICHSELBAUM, A. 1878. Die feineren Veränderungen des Gelenkknoperpels bei fungöser Synovitis und Caries der Gelenkenden. Arch. Pathol. Anat. Physiol. Klin. Med. 461-475.
2. WINCHESTER, R.J. 1981. Genetic aspects of rheumatoid arthritis. Springer Semin. Immunopathol. 4: 89-102.
3. HYRICH, K.L. & R.D. INMAN. 2001. Infectious agents in chronic rheumatic diseases. Curr. Opin. Rheumatol. 13: 300-304.
4. GORONZY, J.J. & C.M. WEYAND. 1995. T cells in rheumatoid arthritis. Paradigms and facts. Rheum. Dis. Clin. North Am. 21: 655-674.
5. STEINER, G. & J. SMOLEN. 2002. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res. 4 (Suppl 2): S1-S5.
6. COOKE, T.D., E.R. HURD, H.E. JASIN, et al. 1975. Identification of immunoglobulins and complement in rheumatoid articular collagenous tissues. Arthritis Rheum. 18: 541-551.
7. DEBETS, J.M., C.J. VAN DER LINDEN, I.E. DIETEREN, et al. 1988. Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. J. Immunol. 141: 1197-1201.
8. HARAOUI, B., J.P. PELLETIER, J.M. CLOUTIER, et al. 1991. Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs. Arthritis Rheum. 34: 153-163.
9. SWEENEY, S.E. & G.S. FIRESTEIN. 2004. Rheumatoid arthritis: regulation of synovial inflammation. Int. J. Biochem. Cell Biol. 36: 372-378.
10. GRAVALLESE, E.M. 2002. Bone destruction in arthritis. Ann. Rheum. Dis. 61 (Suppl 2): ii84-ii86.
11. PERLMUTTER, D.H., C.A. DINARELLO, P.I. PUNSAL & H.R. COLTEN. 1986. Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J. Clin. Invest. 78: 1349-1354.
12. TARTAGLIA, L.A. & D.V. GOEDDEL. 1992. Two TNF receptors. Immunol. Today 13: 151-153.
13. DINARELLO, C.A., J.G. CANNON, S.M. WOLFF, et al. 1986. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J. Exp. Med. 163: 1433-1450.
14. CHU, C.Q., M. FIELD, S. ALLARD, et al. 1992. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br. J. Rheumatol. 31: 653-661.
15. STEINER, G., M. TOHIDAST-AKRAD, G. WITZMANN, et al. 1999. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 38: 202-213.
16. PARTSCH, G., G. STEINER, B.F. LEEB, et al. 1997. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol. 24: 518-523.
17. CHU, C.Q., M. FIELD, M. FELDMANN & R.N. MAINI. 1991. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34: 1125-1132.
18. LAM, J., S. TAKESHITA, J.E. BARKER, et al. 2000. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106: 1481-1488.
19. JORGENSEN, C., I. COURET, F. CANOVAS, et al. 1996. Mononuclear cell retention in rheumatoid synovial tissue engrafted in severe combined immunodeficient (SCID) mice is up-regulated by tumour necrosis factor-alpha (TNF-alpha) and mediated through intercellular adhesion molecule-1 (ICAM-1). Clin. Exp. Immunol. 106: 20-25.
20. FIRESTEIN, G.S. & M.M. PAINE. 1992. Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium. Am. J. Pathol. 140: 1309-1314.
21. KEFFER, J., L. PROBERT, H. CAZLARIS, et al. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10: 4025-4031.
22. SCHETT, G., K. REDLICH, S. HAYER, et al. 2003. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum. 48: 2042-2051.
23. ZWERINA, J., S. HAYER, M. TOHIDAST-AKRAD, et al. 2004. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 50: 277-290.
24. LEWTHWAITE, J., S. BLAKE, T. HARDINGHAM, et al. 1995. Role of TNF alpha in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNF alpha neutralising monoclonal antibodies. Ann. Rheum. Dis. 54: 366-374.
25. THORBECKE:, G.J., R. SHAH, C.H. LEU, et al. 1992. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 89: 7375-7379.
26. LIPSKY, P.E., D.M. VAN DER HEIJDE, E.W. ST. CLAIR, et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343: 1594-1602.
27. MAINI, R., E.W. ST. CLAIR, F. BREEDVELD, et al. 1999. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932-1939.
28. MAINI, R.N., F.C. BREEDVELD, J.R. KALDEN, et al. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41: 1552-1563.
29. MORELAND, L.W., M.H. SCHIFF, S.W. BAUMGARTNER, et al. 1999. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130: 478-486.
30. VAN DE PUTTE, L.B., C. ATKINS, M. MALAISE, et al. 2004. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63: 508-516.
31. WEINBLATT, M.E., E.C. KEYSTONE, D.E. FURST, et al. 2003. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48: 35-45.
32. GENOVESE, M.C., J.M. BATHON, R.W. MARTIN, et al. 2002. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46: 1443-1450.
33. SMOLEN, J.S., C. HAN, M. BALA, et al. 2005. Evidence of radiographic benefit of infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of the ATTRACT trial. Arthritis Rheum. 52: 1020-1030.
34. ST. CLAIR, E.W., D.M. VAN DER HEIJDE, J.S. SMOLEN, et al. 2004. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50: 3432-3443.
35. QUINN, M.A., P.G. CONAGHAN, P.J. O'CONNOR, et al. 2005. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52: 27-35.
36. VAN VOLLENHOVEN, R., A. HARJU, S. BRANNEMARK & L. KLARESKOG. 2003. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann. Rheum. Dis. 62: 1195-1198.
37. DINARELLO, C.A. 1991. Interleukin-1 and interleukin-1 antagonism. Blood 77: 1627-1652.
38. AREND, W.P., H.G. WELGUS, R.C. THOMPSON & S.P. EISENBERG. 1990. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J. Clin. Invest. 85: 1694-1697.
39. DINARELLO, C.A. 2002. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. 20: S1-S13.
40. FOX, S.W., K. FULLER & T.J. CHAMBERS. 2000. Activation of osteoclasts by interleukin-1: divergent responsiveness in osteoclasts formed in vivo and in vitro. J. Cell Physiol. 184: 334-340.
41. LORENZO, J.A., A. NAPRTA, Y. RAO, et al. 1998. Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 139: 3022-3025.
42. KOBAYASHI, M., G.R. SQUIRES, A. MOUSA, et al. 2005. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum. 52: 128-135.
43. RATHANASWAMI, P., M. HACHICHA, W.L. WONG, et al. 1993. Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on interleukin-8 gene expression in synovial fibroblasts. Evidence that interleukin-8 is the major neutrophil-activating chemokine released in response to monokine activation. Arthritis Rheum. 36: 1295-1304.
44. COXON, A., B. BOLON, J. ESTRADA, et al. 2002. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum. 46: 2604-2612.
45. PETTIPHER, E.R., G.A. HIGGS & B. HENDERSON. 1986. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc. Natl. Acad. Sci. USA 83: 8749-8753.
46. KIM, J.M., J.G. JEONG, S.H. HO, et al. 2003. Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. Gene Ther. 10: 1543-1550.
47. PALMER, G., D. TALABOT-AYER, L. SZALAY-QUINODOZ, et al. 2003. Mice transgenic for intracellular interleukin-1 receptor antagonist type 1 are protected from collagen-induced arthritis. Eur. J. Immunol. 33: 434-440.
48. JOOSTEN, L.A., M.M. HELSEN, T. SAXNE, et al. 1999. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J. Immunol. 163: 5049-5055.
49. VAN DEN BERG, W.B., L.A. JOOSTEN, M. HELSEN & F.A. VAN DE LOO. 1994. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. Immunol. 95: 237-243.
50. HORAI, R., S. SAIJO, H. TANIOKA, et al. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191: 313-320.
51. WOOLEY, P.H., J.D. WHALEN, D.L. CHAPMAN, et al. 1993. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum. 36: 1305-1314.
52. FONTANA, A., H. HENGARTNER, E. WEBER, et al. 1982. Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol. Int. 2: 49-53.
53. DELEURAN, B.W., C.Q. CHU, M. FIELD, et al. 1992. Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br. J. Rheumatol. 31: 801-809.
54. MULLER-LADNER, U., C.R. ROBERTS, B.N. FRANKLIN, et al. 1997. Human IL-IRa gene transfer into human synovial fibroblasts is chondroprotective. J. Immunol. 158: 3492-3498.
55. CAMPION, G.V., M.E. LEBSACK, J. LOOKABAUGH, et al. 1996. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-IRa Arthritis Study Group. Arthritis Rheum. 39: 1092-1101.
56. BRESNIHAN, B., J.M. ALVARO-GRACIA, M. COBBY, et al. 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41: 2196-2204.
57. COHEN, S., E. HURD, J. CUSH, et al. 2002. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46: 614-624.
58. SHERGY, W.J., S. COHEN, M.W. GREENWALD, et al. 2003. Anakinra (Kineret) inhibits the progression of radiographically measured joint destruction in rheumatoid arthritis. Ann. Rheum. Dis. 62: 273.
59. COHEN, S.B., L.W. MORELAND, J.J. CUSH, et al. 2004. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63: 1062-1068.
60. GULER, H.P. et al. 2001. A phase I, single dose escalation study of IL-1 trap in patients with rheumatoid arthritis. Arthritis Rheum. 44: 370.
61. PAVELKA, K. et al. 2002. Clinical effects of pralnacasan (PRAL), an orally active interleukin-1beta converting enzyme (ICE) inhibitor in a 285-patient phase II trial in rheumatoid arthritis (RA). Arthritis Rheum. 48: 281.
62. TOSATO, G., K.B. SEAMON, N.D. GOLDMAN, et al. 1988. Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6). Science 239: 502-504.
63. OKADA, M., N. SAKAGUCHI, N. YOSHIMURA, et al. 1983. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J. Exp. Med. 157: 583-590.
64. HIBI, M., K. NAKAJIMA & T. HIRANO. 1996. IL-6 cytokine family and signal transduction: a model of the cytokine system. J. Mol. Med. 74: 1-12.
65. YOSHIZAKI, K., T. NAKAGAWA, T. KAIEDA, et al. 1982. Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors. J. Immunol 128: 1296-1301.
66. NISHIMOTO, N., A. OGATA, Y. SHIMA, et al. 1994. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J. Exp. Med. 179: 1343-1347.
67. ISHIBASHI, T., H. KIMURA, T. UCHIDA, et al. 1989. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc. Natl. Acad. Sci. USA 86: 5953-5957.
68. IKEBUCHI, K., G.G. WONG, S.C. CLARK, et al. 1987. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc. Natl. Acad. Sci. USA 84: 9035-9039.
69. GOYA, S., H. MATSUOKA, M. MORI, et al. 2003. Sustained interleukin-6 signalling leads to the development of lymphoid organ-like structures in the lung. J. Pathol. 200: 82-87.
70. HILL, R.J., M.K. WARREN, P. STENBERG, et al. 1991. Stimulation of megakaryocytopoiesis in mice by human recombinant interleukin-6. Blood 77: 42-48.
71. SUEMATSU, S., T. MATSUDA, K. AOZASA, et al. 1989. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. USA 86: 7547-7551.
72. FATTORI, E., R.C. DELLA, P. COSTA, et al. 1994. Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood 83: 2570-2579.
73. KATSUME, A., H. SAITO, Y. YAMADA, et al. 2002. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 20: 304-311.
74. HOUSSIAU, F.A., J.P. DEVOGELAER, J. VAN DAMME, et al. 1988. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 31: 784-788.
75. GUERNE, P.A., B.L. ZURAW, J.H. VAUGHAN, et al. 1989. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J. Clin. Invest. 83: 585-592.
76. OKAMOTO, H., M. YAMAMURA, Y. MORITA, et al. 1997. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 40: 1096-1105.
77. POLI, V., R. BALENA, E. FATTORI, et al. 1994. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13: 1189-1196.
78. BELLIDO, T., R.L. JILKA, B.F. BOYCE, et al. 1995. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J. Clin. Invest. 95: 2886-2895.
79. KUDO, O., A. SABOKBAR, A. POCOCK, et al. 2003. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32: 1-7.
80. KURIHARA, N., D. BERTOLINI, T. SUDA, et al. 1990. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J. Immunol. 144: 4226-4230.
81. TAKAGI, N., M. MIHARA, Y. MORIYA, et al. 1998. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 41: 2117-2121.
82. MIHARA, M., M. KOTOH, N. NISHIMOTO, et al. 2001. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin. Immunol. 98: 319-326.
83. SASAI, M., Y. SAEKI, S. OHSHIMA, et al. 1999. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 42: 1635-1643.
84. ALONZI, T., E. FATTORI, D. LAZZARO, et al. 1998. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187: 461-468.
85. WENDLING, D., E. RACADOT & J. WIJDENES. 1993. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. 20: 259-262.
86. YOSHIZAKI, K., T. MATSUDA, N. NISHIMOTO, et al. 1989. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74: 1360-1367.
87. NISHIMOTO, N., M. SASAI, Y. SHIMA, et al. 2000. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95: 56-61.
88. CHOY, E.H., D.A. ISENBERG, T. GARROOD, et al. 2002. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 46: 3143-3150.
89. NISHIMOTO, N., K. YOSHIZAKI, N. MIYASAKA, et al. 2004. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50: 1761-1769.
90. GRABSTEIN, K.H., J. EISENMAN, K. SHANEBECK, et al. 1994. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264: 965-968.
91. DOHERTY, T.M., R.A. SEDER & A. SHER. 1996. Induction and regulation of IL-15 expression in murine macrophages. J. Immunol. 156: 735-741.
92. KANEGANE, H. & G. TOSATO. 1996. Activation of naive and memory T cells by interleukin-15. Blood 88: 230-235.
93. MCINNES, I.B., J. AL MUGHALES, M. FIELD, et al. 1996. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. 2: 175-182.
94. CARSON, W.E., J.G. GIRI, M.J. LINDEMANN, et al. 1994. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180: 1395-1403.
95. ALLEVA, D.G., S.B. KASER, M.A. MONROY, et al. 1997. IL-15 functions as a potent autocrine regulator of macrophage proinflammatory cytokine production: evidence for differential receptor subunit utilization associated with stimulation or inhibition. J. Immunol. 159: 2941-2951.
96. OGATA, Y., A. KUKITA, T. KUKITA, et al. 1999. A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2. J. Immunol. 162: 2754-2760.
97. THURKOW, E.W., I.M. VAN DER HEIJDEN, F.C. BREEDVELD, et al. 1997. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J. Pathol. 181: 444-450.
98. MCINNES, I.E., B.P. LEUNG, R.D. STURROCK, et al. 1997. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat. Med. 3: 189-195.
99. MIRANDA-CARUS, M.E., A. BALSA, M. BENITO-MIGUEL, et al. 2004. IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate. J. Immunol. 173: 1463-1476.
100. GRACIE, J.A., R.J. FORSEY, W.L. CHAN, et al. 1999. A proinflammatory role for IL-18 in rheumatoid arthritis. J. Clin. Invest. 104: 1393-1401.
101. RUCHATZ, H., B.P. LEUNG, X.Q. WEI, et al. 1998. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J. Immunol. 160: 5654-5660.
102. FERRARI-LACRAZ, S., E. ZANELLI, M. NEUBERG, et al. 2004. Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J. Immunol. 173: 5818-5826.
103. MCINNES, I.B. & J.A. GRACIE. 2004. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr. Opin. Pharmacol. 4: 392-397.
104. MCINNES, I., R. MARTIN, I. ZIMMERMAN-GORSKA, et al. 2004. Safety and efficacy of a human monoclonal antibody to IL-15 (AMG 714) in patients with rheumatoid arthritis (RA): results from a multicenter, randomized, double-blind, placebo-controlled trial. Presented at the Annual Meeting of the American College of Rheumatology. San Antonio, TX, Oct 18.
105. SMOLEN, J.S. & G. STEINER. 2003. Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov. 2: 473-488.
106. REDLICH, K., B. GORTZ, S. HAYER, et al. 2004. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am. J. Pathol. 164: 543-555.